Clinical trials: Influenza, Human, open to volunteers
Covid 19, Influenza
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
2. Participants will: Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. Visit the clinic on the 7th day of treatment for a check-up and safety tests.
- Trial name
- NCT06817096
- Volunteers
- 340 people
- Sponsor
- Azidus Brasil
Influenza, Human, Influenza, Human Prevention
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
- Trial name
- NCT06800950
- Testing
- QIV, QIV Control
- Where
- 3 sites in China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Influenza, Influenza Prophylaxis
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical…
- Conditions
- Influenza, Influenza Prophylaxis, Nosocomial Infection
- Trial name
- NCT06762587
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- China
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Influenza, Acute Respiratory Distress Syndrome
The Role of Cxcr4Hi neutrOPhils in InflueNza
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research.
- Trial name
- CHOPIN (NCT06254313)
- Testing
- Additional tubes and LBA
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
Influenza
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
Index patients who are infected with influenza virus (Q-PCR positive) can be treated with anti-influenza drugs if their influenza symptoms onset was within 48 hours of screening.
- Trial name
- NCT06574503
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 748 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Influenza, Human
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
- Trial name
- NCT06573008
- Testing
- GP681 40mg, GP681 Simulant
- Where
- China
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19, Influenza
Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection
This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus…
- Trial name
- NCT06667063
- Testing
- Nasal swab/Nasopharyngeal swab/Blood sample collection, Nasal swab/Nasopharyngeal swab/Blood draw
- Where
- 2 sites in China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Influenza Vaccines
Vaccine Chatbot for Improving Influenza Vaccination Uptake
This study aims to assess the impact of a vaccine chatbot on improving influenza vaccination uptake among children aged between 6 and 59 months through a cluster randomized trial.
- Trial name
- NCT06657573
- Testing
- An AI-enabled chatbot tailored for influenza vaccine consultation
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Fudan University
Community-acquired Pneumonia, Influenza, COVID-19
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients…
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Influenza Vaccine Allergy
Influenza Vaccine Effectiveness in Among Young Children in Taiwan
This project uses questionnaires to statistically analyze whether influenza vaccination is protective for young children.
- Trial name
- NCT06446232
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- National Taiwan University Hospital
Otitis, Bronchiolitis
Pediatric and Ambulatory Research in Infectious Diseases
Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network.
- Conditions
- Otitis, Bronchiolitis, Influenza, Pharyngitis
- Trial name
- PARI (NCT04471493)
- Where
- France
- Volunteers
- 400,000 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Influenza
Bone Marrow and Peripheral Blood Immune Responses Study
The purpose of this study is to evaluate the immune response of the killed flu vaccine in healthy subjects. Participants in this study are considered to be healthy volunteers.
- Trial name
- NCT05616546
- Testing
- Influenza Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Emory University